Oncobiologics appoints Kenyon as CEO, president

By Emily Bader
Cranbury | Aug 3, 2018 at 11:56 am

Oncobiologics Inc., a Cranbury-based biopharmaceutical company, announced Thursday that Lawrence A. Kenyon, its chief financial officer and corporate secretary, has been promoted to CEO and president, and has joined its board of directors as a class II director.

Kenyon will remain as CFO until a replacement is found, Oncobiologics said.

“On behalf of the Oncobiologics board of directors, we are very pleased to name Larry as President and CEO as well as his appointment to the board of directors,” said Randy Thurman, executive chairman, Oncobiologics.  “Larry’s experience and demonstrated leadership are an ideal fit for Oncobiologics as we move our lead program into the clinic and address the other strategies instrumental to the company’s success.  The company’s senior leadership team is an ideal complement to Larry’s background and represents one of the best in the biopharma industry.”

Kenyon was appointed interim CEO at the company in June 2018. He has more than 20 years of leadership experience in the life sciences industry, including working as CFO and chief operating officer at Arno Therapeutics Inc.; CEO, interim president, CFO and secretary at Tamir Biotechnology Inc.; executive vice president and CFO at Par Pharmaceuticals Companies Inc.; CFO and COO at Alfacell Corp.; and EVP and CFO at NeoPharm Inc.

“I am honored by the trust and confidence shown by the board,” Kenyon said. “Our lead asset, ONS-5010, presents an exciting opportunity to meet the need for an important and affordable therapeutic option for patients. I look forward to working with the board and our very talented senior leadership team to execute on our strategy to maximize value for all Oncobiologics stockholders.”

Emily Bader | ebader@roi-nj.com | emilybader